Chemistry:Otlertuzumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | CD37 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C4660H7136N1246O1452S30 |
| Molar mass | 104809.42 g·mol−1 |
Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]
References
- ↑ "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters 40 (11–12): 1459–1466. December 2018. doi:10.1007/s10529-018-2612-6. PMID 30293139.
- ↑ "Otlertuzumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. http://www.ama-assn.org/resources/doc/usan/otlertuzumab.pdf.
- ↑ "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/results?cond=&term=Otlertuzumab&cntry=&state=&city=&dist=&Search=Search.
